drugset / Trial / NCT05741359
The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma
Phase 1
Recruiting
18 enrolled
Bioray Laboratories
Chinese Academy of Medical Sciences · collabUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology · collabZhejiang University · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a multi-center, single-arm, open-label clinical study, and the sample size is set to 12-18 subjects.
Timeline
- Start
- 2023-04-25
- Primary completion
- 2026-11-20
- Completion
- 2027-01-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection | Cell therapy | 5e+06 cells/kg | — |
| Subject | CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection | Cell therapy | 1e+07 cells/kg | — |